Office Hours with Senator Richard Burr
Webcast series on legislative developmentsStrategic guidance for responding to evolving regulations
Get timely guidance on the rapidly changing legal and regulatory environment shaped by the current administration and congressional priorities.
Drawing on Senator Burr’s deep experience and insider perspective, this webcast series offers actionable insights into Capitol Hill developments that impact businesses and stakeholders across industries.
Stay informed on emerging legislation, regulatory updates, and strategic considerations to help you anticipate and adapt to policy changes.
To learn more about our Regulatory and Government Affairs practice, visit dlapiper.com or contact Che Webb.
Upcoming sessions
Delivering insider perspectives, each episode is built for the moment: responsive to fast‑moving developments and the real‑time questions organizations are asking.
Join us as we unpack the regulatory shifts and policy changes shaping business.
- March 18, 2026: Policy developments, emerging technology, and the latest on the CHIPS program
- April 14, 2026: Our Capitol Hill insights
February 17 Session Recap
This Office Hours session examines how congressional investigations have accelerated, become more aggressive, and increasingly pose reputational risk, requiring organizations to prepare well before any inquiry begins.
Key Takeaways
- Investigations are faster and escalate quickly. Committees now move rapidly from information requests to subpoenas, often without extended negotiation or warning.
- Politics and public visibility drive scrutiny. Investigations are shaped by policy priorities, election cycles, and the need for public narratives, not just legislative oversight.
- Reputational risk often outweighs legal risk. Organizations should pre‑identify decision‑makers, response protocols, and privileged communication structures before an inquiry arises.
- AI is accelerating oversight. Artificial intelligence is increasing the speed, scale, and sophistication of investigations by enabling rapid document analysis and narrative formation.
To gain access to the recording of this conversation, reach out to Che Webb.
Session Takeaways
Congress is increasingly focused on artificial intelligence, navigating bipartisan challenges and evolving regulatory approaches to address rapid technological change.
Key takeaways
- Lawmakers are advancing a federal AI framework and sector‑specific rules to support responsible development and innovation.
- Political divisions are shaping proposed AI commissions and regulatory strategies ahead of the 2026 election.
- Executive orders and new legislation aim to create unified national AI standards and prevent conflicting state‑level rules.
- AI is transforming healthcare, robotics, and national security, with federal investment and public‑private partnerships key to U.S. competitiveness.
- Congress is considering age limits, technical safeguards, and privacy protections to address child safety, data security, and consumer risks.
To gain access to the recording of this conversation, reach out to Che Webb.
The session focused on ACA subsidy uncertainty, healthcare’s role in 2026 elections, drug pricing reforms, tariff challenges, and early campaign dynamics.
Key takeaways
- ACA Subsidies – No permanent fix expected; likely a short-term or one-year extension to avoid premium spikes. Trump administration’s stance is key.
- Healthcare & Elections – Democrats will make healthcare the centerpiece of 2026 campaigns, regardless of ACA outcome.
- Drug Pricing – MFN policy and TrumpRx signal lasting pressure on pharma and PBMs; distribution models may shift.
- Trade & Tariffs – Supreme Court may strike IEPA tariffs; administration could pivot to other tools, impacting costs and supply chains.
- Campaign Timing – Midterms will start early (spring 2026), leaving a 90-day legislative window; GOP faces tough odds after recent underperformance.
To gain access to the recording of this conversation, reach out to Che Webb.
The session focused on ACA subsidy uncertainty, healthcare’s role in 2026 elections, drug pricing reforms, tariff challenges, and early campaign dynamics.
Key Takeaways
- ACA Subsidies – No permanent fix expected; likely a short-term or one-year extension to avoid premium spikes. Trump administration’s stance is key.
- Healthcare & Elections – Democrats will make healthcare the centerpiece of 2026 campaigns, regardless of ACA outcome.
- Drug Pricing – MFN policy and TrumpRx signal lasting pressure on pharma and PBMs; distribution models may shift.
- Trade & Tariffs – Supreme Court may strike IEPA tariffs; administration could pivot to other tools, impacting costs and supply chains.
- Campaign Timing – Midterms will start early (spring 2026), leaving a 90-day legislative window; GOP faces tough odds after recent underperformance.
To gain access to the recording of this conversation, reach out to Che Webb.
More from DLA Piper
FDA in Focus: 2025 review and 2026 outlook
In 2025, FDA concentrated on rebuilding and modernizing its internal infrastructure amid unprecedented organizational and leadership changes. Against the backdrop of a significant reduction in force, shifting regulatory philosophies, and evolving policy priorities, the Agency focused on strengthening food safety, advancing medical product innovation, and enhancing oversight across its programs.
Consumer Goods | Speaker Series
Stay ahead of the curve with these CLE webinars on today’s most pressing regulatory issues related to Consumer Goods.
Designed for regulatory professionals, compliance officers, legal counsel, and business leaders in consumer goods and retail.
- Expert Perspectives: Hear from leading practitioners on topics shaping the regulatory landscape.
- Deep-Dive Sessions: Explore critical areas such as FTC enforcement trends, arbitration developments, post-acquisition integration risks, extended producer responsibility (EPR), and M&A compliance considerations.
- Practical Guidance: Gain strategies to mitigate risk and ensure compliance in a rapidly evolving market.
Stay Informed: FDA Regulatory News and Trends
Keep pace with the latest developments impacting the life sciences and healthcare sectors. DLA Piper’s FDA Regulatory News and Trends provides timely insights on:
- Policy Shifts & Guidance Updates: Understand evolving FDA regulations and compliance expectations.
- Enforcement Priorities: Learn what recent actions signal for manufacturers and stakeholders.
- Emerging Issues: Explore topics such as product approvals, labeling requirements, and risk management strategies.
This resource is essential for regulatory professionals, legal counsel, and industry leaders seeking clarity in a complex regulatory environment.
